(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.49%) $79.65
(0.39%) $2.31
(0.53%) $2 352.70
(0.69%) $28.56
(0.20%) $992.80
(-0.29%) $0.927
(-0.37%) $10.85
(-0.24%) $0.798
(0.90%) $92.56
Quarter results today
(bmo 2024-05-09)
Expected move: +/- 9.30%
0.22% $ 0.732
@ $1.235
Emitido: 12 feb 2024 @ 15:35
Retorno: -40.76%
Señal anterior: feb 12 - 14:01
Señal anterior:
Retorno: 2.06 %
Live Chart Being Loaded With Signals
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform...
Stats | |
---|---|
Volumen de hoy | 909 888 |
Volumen promedio | 1.68M |
Capitalización de mercado | 129.37M |
EPS | $0 ( 2024-05-02 ) |
Próxima fecha de ganancias | ( $-0.140 ) 2024-08-01 |
Last Dividend | $12.19 ( 2012-11-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.280 |
ATR14 | $0.00400 (0.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-28 | Tucker Sean | Buy | 0 | |
2024-03-28 | Tucker Sean | Sell | 3 902 | Common Stock |
2024-03-28 | Cummings James F. | Sell | 3 292 | Common Stock |
2024-03-18 | Tucker Sean | Buy | 90 000 | Common Stock |
2024-03-18 | Tucker Sean | Buy | 410 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
94.61 |
Last 95 transactions |
Buy: 10 890 181 | Sell: 279 805 |
Volumen Correlación
Vaxart Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
LYEL | 0.934 |
LYRA | 0.93 |
BNIXU | 0.929 |
TCRT | 0.92 |
WISA | 0.915 |
GROM | 0.914 |
AFMD | 0.914 |
ARQQ | 0.914 |
GRNA | 0.913 |
BNOX | 0.912 |
10 Correlaciones Más Negativas | |
---|---|
LRFC | -0.93 |
STAY | -0.928 |
GLLI | -0.907 |
IBEX | -0.905 |
OSMT | -0.904 |
XOMAO | -0.899 |
CHPM | -0.898 |
XOMAP | -0.898 |
BCOR | -0.895 |
MNKD | -0.893 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Vaxart Inc Correlación - Moneda/Commodity
Vaxart Inc Finanzas
Annual | 2023 |
Ingresos: | $7.38M |
Beneficio Bruto: | $2.88M (39.02 %) |
EPS: | $-0.570 |
FY | 2023 |
Ingresos: | $7.38M |
Beneficio Bruto: | $2.88M (39.02 %) |
EPS: | $-0.570 |
FY | 2022 |
Ingresos: | $107 000 |
Beneficio Bruto: | $-3.16M (-2 953.27 %) |
EPS: | $-0.840 |
FY | 2021 |
Ingresos: | $892 000 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.580 |
Financial Reports:
No articles found.
Vaxart Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $12.19 | 2012-11-09 |
Last Dividend | $12.19 | 2012-11-09 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $12.19 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $12.19 | 9.77% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -14.41 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.898 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.085 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.32 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.11 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.53 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0994 | -1.500 | 8.34 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -57.60 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.459 | 2.00 | -0.153 | -0.306 | [0 - 30] |
freeCashFlowPerShareTTM | -0.471 | 2.00 | -0.236 | -0.471 | [0 - 20] |
debtEquityRatioTTM | 0.158 | -1.500 | 9.37 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.196 | 1.000 | -0.0722 | -0.0722 | [0.2 - 0.8] |
operatingProfitMarginTTM | -14.56 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -7.72 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0623 | 0.800 | -2.92 | -2.33 | [0.5 - 2] |
Total Score | -1.818 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.358 | 1.000 | -0.238 | 0 | [1 - 100] |
returnOnEquityTTM | -1.085 | 2.50 | -8.46 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.471 | 2.00 | -0.157 | -0.471 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.459 | 2.00 | -0.153 | -0.306 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -12.31 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.59 |
Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico